NSABP FC-12

NSABP FC-12

A Single Arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy

Protocol Chair: Priya Rastogi, MD

Protocol Officer: Shannon Puhalla, MD

Patient Population:
Patients with Stage II/III Colon Cancer who are ctDNA-positive after Curative Surgery and Adjuvant Chemotherapy

Target Accrual: 31 patients

Status: Active, Not Recruiting

ClinicialTrials.gov Identifier: NCT05178576